Overview
What the CCGC Is
The Chinese Cancer Genome Consortium (CCGC) was organized in August 2008 as a publicly-funded network with over 30 university hospitals and research institutions, launched to coordinate large-scale cancer genome studies in China. It followed International Cancer Genome Consortium (ICGC) standards for biospecimen collection and quality control. nih
The CCGC became China's representative member of the ICGC international collaboration, led by Henry Yang and Youyong Lu.
CCGC's Primary Cancer Focus — Not Gynecologic
It's important to be direct here: gynecologic cancers were never the primary output of the CCGC. While the CCGC announced approximately 15 types of common cancers in China to be initiated — including gastric, hepatocellular, esophageal, nasopharyngeal, colorectal, bladder, lung, thyroid, breast, renal, ovarian, and pancreatic cancer, leukemia, and glioblastoma — the consortium's most productive output has been in gastric cancer genomics. The first cancer genome explorations from the CCGC were reported from Rui Jin Hospital, Shanghai, focusing on AML and gastric cancer, with DNMT3A mutation discovery in leukemia being an early landmark. There is no major CCGC-branded ovarian, endometrial, or cervical cancer whole-genome sequencing dataset comparable to, for example, the AOCS ICGC contribution.
What Does Exist: Chinese Gynecologic Cancer Genomics More Broadly
While the CCGC itself hasn't produced prominent gynecologic cancer genomics outputs, there is a growing body of Chinese institutional genomics work in this space worth knowing:
Ovarian Cancer: A large cross-sectional study retrospectively enrolled 1,610 unselected Chinese gynecologic cancer patients (945 with ovarian cancer, 307 with endometrial cancer, 358 with cervical cancer) who underwent tumor-normal sequencing using a 520-gene panel between October 2017 and May 2021, assessing germline variants in 62 cancer predisposition genes.
Pan-Gynecologic Mutation Profiling: A whole-exome sequencing study in 209 Chinese gynecologic cancer patients (74 cervical, 68 endometrial, 67 ovarian) examined the mutation landscape and validated results with TCGA cohorts, finding significant consistency between Chinese and Western data.
Endometrial Cancer: Chinese researchers at Fudan University Shanghai Cancer Center have published genomic profiles of Chinese endometrial carcinoma patients, with molecular subtyping using NGS panels targeting POLE, TP53, and MSI status — including a retrospective cohort of 479 cases.
Cervical Cancer: A study of 129 Chinese cervical cancer patients using targeted NGS of 618 genes — comparing Chinese vs. Western (TCGA) genomic profiles — found significantly different prevalences of TP53, KMT2C, and RET alterations between the two populations, with DDR gene alterations being notably prevalent in the Chinese cohort.
Ovarian Clear Cell Carcinoma: Given that clear cell ovarian cancer is substantially more common in East Asian populations than in Western ones, Chinese and Japanese cohorts have been particularly important for clear cell genomics. An 80-patient Chinese OCCC cohort characterized by a 520-gene panel found ARID1A (49%) and PIK3CA (48%) as the most commonly mutated genes, with MSI-high observed in 6.3% of patients — findings with direct therapeutic implications for immune checkpoint inhibitor use.
Why This Matters for Gynecologic Oncology
China has a distinct gynecologic cancer epidemiology compared to Western populations — notably a higher incidence of cervical cancer, a higher proportion of clear cell ovarian carcinoma, and potentially different BRCA1/2 variant spectra. The key value of Chinese genomics data for gynonc is therefore not primarily through the CCGC as an institutional entity, but through the growing number of institutional sequencing studies from major Chinese cancer centers (Fudan/Shanghai, Peking University, Chinese PLA General Hospital), which are revealing population-specific mutation frequencies, germline variant landscapes, and molecular subtype distributions. This data is increasingly informing how TCGA-derived classification frameworks (especially for endometrial cancer) apply — or need adaptation — in East Asian patients.
Notes
Established August 2008. Coordinates genomic research across China. Publicly-funded collaborative network. Parallel to international efforts like TCGA.